HPV vaccine for all

The Lancet

Volumn 374, Issue 9686, 2009, Pages 268-270

  Michels, Karin B ^a,b   zur Hausen, Harald ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER SCREENING; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEALTH PROGRAM; HERD IMMUNITY; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PERSISTENT INFECTION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TUMOR IMMUNITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS RECOMBINANT; WART VIRUS;

EID: 67651042998     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61247-2     Document Type: Note

References (12)

1. Dürst M., Gissmann L., Ikenberg H., and zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80 (1983) 3812-3815
2. Boshart M., Gissmann L., Ikenberg H., Kleinheinz A., Scheurlen W., and zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer and in cell lines derived from genital cancer. EMBO J 3 (1984) 1151-1157
3. Paavonen J., Naud P., Salmerón J., et al., for the HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet (2009) 10.1016/S0140-6736(09)61248-4 published online July 7.
4. Einstein MH, on behalf of the HPV 010 study group. Immune response after primary vaccination course: a comparative trial of two HPV prophylactic vaccines. 25th International Papillomavirus Conference, Malmö, Sweden; May 8-14, 2009: O-01.02 (abstr).
5. Wheeler C.M., Kjaer S.K., Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199 (2009) 936-944
6. Schwartz T.F., and Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 110 suppl 1 (2008) S1-S10
7. Block S.L., Nolan T., Sattler C., et al., for the Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006) 2135-2145
8. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 297 (2007) 813-819
9. Dunne E.F., Nielson C.M., Stone K.M., Markowitz L.E., and Giuliano A.R. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 194 (2006) 1044-1057
10. Stanley M. Immune response to human papillomavirus. Vaccine 24 suppl 1 (2006) S16-S22
11. Insinga R.P., Dasbach E.J., and Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 36 (2003) 1397-1403
12. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 (2007) 28-41